Innogen again appears in the Future Healthcare Top 100
On 6 May, VB100, VCBeat and the Eggshell Research Institute released the 2023 Future Healthcare Top 100 lists. Innogen appeared in the China Innovative Biopharmaceutical Companies list for a second consecutive year, receiving the organisers’ recognition of its technical capabilities and industry position.
Launched in 2015 by VB100, VCBeat and the Eggshell Research Institute, the Future Healthcare Top 100 series was China’s first innovative-healthcare ranking focused on unlisted businesses. It aims to identify Chinese innovators with the potential to shape healthcare and support industry change. Using the VB100 valuation model, selection proceeds through company applications, VB100 review, cross-review by supporting institutions and final expert-committee assessment. It identifies the top 100 companies by valuation in each of five fields: medical devices, biopharmaceuticals, digital health, healthcare services, and commercial and supply-chain services. Beyond valuation, it considers growth and annual performance across human resources, knowledge resources, key partnerships and market performance, comprising 17 underlying measures.
About Innogen
Innogen is a science-driven biopharmaceutical company seeking to provide innovative, accessible, affordable and high-quality medicines for people with metabolic diseases. It has multiple internally developed programs for diabetes, obesity and non-alcoholic steatohepatitis, with global patents, and plans to expand research, development and commercial activity internationally.
Its first pipeline product, efsubaglutide alfa, had completed the 24-week double-blind treatment period of Phase III T2DM studies and met the primary efficacy endpoint. The company anticipated that, if approved, it could become China’s first humanised long-acting GLP-1 receptor agonist with independently owned intellectual property. Innogen was also developing weight-loss and non-alcoholic fatty-liver indications to address unmet needs.
Image text and data — 2023 Future Healthcare Top 100: Innovative Biomedicine Companies poster
The poster attached to the original English article reads “TOP 100 BIOMEDICINE COMPANIES,” “China Innovative Biomedicine Companies List,” “2023 Future Healthcare Top 100,” and “Innogen.” A QR code is captioned “Scan to view the ranking.”